Li Qin

300 Xueshi Road
Changsha, 410208, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Celastrol ameliorates atherosclerosis by inhibiting TLR4/STAT3/NLRP3-mediated macrophage pyroptosis.

Celastrol ameliorates atherosclerosis by inhibiting TLR4/STAT3/NLRP3-mediated macrophage pyroptosis.

Journal: Chinese medicine

Published: February 05, 2026

Correction: He et al. Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention. Cells 2024, 13, 1819.

Correction: He et al. Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention. Cells 2024, 13, 1819.

Journal: Cells

Published: January 26, 2026

Celastrol triggers CAV-1-mediated mitochondrion cholesterol metabolism and mitophagy to suppress liver cancer.

Celastrol triggers CAV-1-mediated mitochondrion cholesterol metabolism and mitophagy to suppress liver cancer.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: November 24, 2025

Targeting caveolin-1: dual challenges in tumor immunity and drug therapy strategies.

Targeting caveolin-1: dual challenges in tumor immunity and drug therapy strategies.

Journal: Cancer cell international

Published: November 05, 2025

Targeting pyroptosis in atherosclerosis: emerging pharmacologic strategies and natural compound-based therapeutics-a narrative review.

Targeting pyroptosis in atherosclerosis: emerging pharmacologic strategies and natural compound-based therapeutics-a narrative review.

Journal: International journal of clinical pharmacy

Published: October 21, 2025

Self-assembling RADA16-I peptide in situ hydrogel loaded with Celastrol boost immunogenic cell death in oral squamous cell carcinoma.

Self-assembling RADA16-I peptide in situ hydrogel loaded with Celastrol boost immunogenic cell death in oral squamous cell carcinoma.

Journal: Drug delivery and translational research

Published: July 28, 2025

Correction: Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma.

Correction: Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma.

Journal: Acta pharmacologica Sinica

Published: May 14, 2025

Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention.

Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention.

Journal: Cells

Published: September 21, 2024

Sensitivity of renal cell carcinoma to cuproptosis: a bioinformatics analysis and experimental verification.

Sensitivity of renal cell carcinoma to cuproptosis: a bioinformatics analysis and experimental verification.

Journal: Journal of Cancer

Published: September 15, 2024

Competing endogenous RNAs network dysregulation in oral cancer: a multifaceted perspective on crosstalk and competition.

Competing endogenous RNAs network dysregulation in oral cancer: a multifaceted perspective on crosstalk and competition.

Journal: Cancer cell international

Published: April 26, 2024

Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC.

Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC.

Journal: Current pharmaceutical design

Published: December 26, 2023

Celastrol mediates CAV1 to attenuate pro-tumorigenic effects of senescent cells.

Celastrol mediates CAV1 to attenuate pro-tumorigenic effects of senescent cells.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: November 23, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026